US 7,507,787 B2
	Effectors of innate immunity
Robert E. W. Hancock, Vancouver (Canada); B. Brett Finlay, Richmond (Canada); Monisha Gough Scott, Vancouver (Canada); Dawn Bowdish, Vancouver (Canada); Carrie Melissa Rosenberger, Vancouver (Canada); and Jon-Paul Steven Powers, Vancouver (Canada)
Assigned to The University of British Columbia, Vancouver, British Columbia (Canada)
Filed on Dec. 02, 2002, as Appl. No. 10/308,905.
Claims priority of provisional application 60/336632, filed on Dec. 03, 2001.
Prior Publication US 2004/0001803 A1, Jan. 01, 2004
Int. Cl. A61K 38/00 (2006.01); A61K 38/28 (2006.01); A61K 38/04 (2006.01); C07K 14/00 (2006.01); C07K 16/00 (2006.01)

U.S. Cl. 530—300  [530/305; 530/327]

1 Claim

1. An isolated peptide comprising a general formula X1X2X3IX4PX4IPX5X2X1 (SEQ ID NO: 4), wherein X1 is one or two of R, L or K, X2 is one of C, S or A, X3 is one of R or P, X4 is one of A or V and X5 is one of V or W, and wherein the peptide is LLCRIVPVIPWCK (SEQ ID NO: 5), LRCPIAPVIPVCKK (SEQ ID NO: 6), KSRIVPAIPVSLL (SEQ ID NO: 7), KKSPIAPAIPWSR (SEQ ID NO: 8), RRARIVPAIPVARR (SEQ ID NO: 9) or LSRIAPAIPWAKL (SEQ ID NO: 10).